CDC7-2 Antibody

What is CDC7 and why is it an important research target?

CDC7 is a serine/threonine protein kinase that plays a critical role in cell cycle regulation and DNA replication. It functions by activating key components of the replication stress response, helping to mitigate cancer cells' DNA damage and promote genomic stability . CDC7 requires binding to regulatory subunits (either DBF4 or DRF1) for its kinase activity . Its importance as a research target stems from its essential role in DNA replication initiation and its potential as a therapeutic target in various cancers, including pancreatic adenocarcinoma , breast cancer , and acute myeloid leukemia .

What is the difference between CDC7-DBF4 and CDC7-DRF1 complexes?

In human cells, CDC7 exists in two alternative complexes: CDC7-DBF4 or CDC7-DRF1 . Recent research indicates that while both regulatory subunits can support CDC7's essential function for bulk DNA replication, DBF4 is the primary mediator of CDC7 activity during DNA replication . DBF4-deficient cells show altered replication efficiency, partial deficiency in MCM helicase phosphorylation, and alterations in replication timing of specific genomic regions. Notably, CDC7 function at replication forks is entirely dependent on DBF4 and not on DRF1 . When designing experiments with CDC7 antibodies, researchers should consider which complex they're targeting and understand that interfering with DBF4 may have more significant effects on DNA replication than targeting DRF1.

How does CDC7 expression differ between normal and cancer cells?

Studies have shown markedly higher expression levels of CDC7 protein in cancer tissues compared to normal tissue. For example, in pancreatic ductal and ampullary cancers, CDC7 is expressed at significantly higher levels compared to benign pancreatic tissue (median LI 34.3%, IQR 28.6 to 63.4% vs. median LI 1.3%, IQR 0.3 to 2.9%; P<0.0001) . In normal primary cell lines, CDC7 levels are very low or absent, while approximately 50% of cancer cell lines show increased CDC7 expression relative to β-actin . There is also a strong association between high CDC7 expression levels and mutated TP53, with 90% of mutant p53 cancer cell lines overexpressing CDC7 .

How does CDC7 inhibition differentially affect cancer cells versus normal cells?

A key finding in CDC7 research is the differential response between normal cells and cancer cells to CDC7 inhibition. When CDC7 is depleted or inhibited in cancer cells, particularly those with p53 mutations, cells enter an abortive S phase followed by apoptotic cell death . This occurs because cancer cells lack a p53-dependent Cdc7-inhibition checkpoint. In contrast, normal cells with functional p53 avoid entering a lethal S phase by engaging a DNA origin activation checkpoint that reversibly arrests cells in G1 phase until CDC7 levels are restored . This mechanistic difference provides a therapeutic window for CDC7-targeting strategies, making antibodies against CDC7 valuable tools for studying these differential responses in various cell types.

What is the relationship between CDC7 expression and replication timing (RT) alterations?

Recent research indicates that CDC7 activity, particularly through the DBF4 regulatory subunit, influences replication timing across the genome. DBF4-deficient cells show changes in RT that are consistent with reduced origin activation. This leads to delays in regions sparse in origins (which rely on passive replication), while regions with high origin density have higher chances of being activated even with compromised CDC7 activity . These RT changes show similarities to those observed in RIF1-deficient cells but maintain a higher degree of distinction between early and late replicating domains . When using CDC7 antibodies for chromatin immunoprecipitation or related techniques, researchers should consider how CDC7 might be differentially distributed across the genome at different cell cycle phases.

How does CDC7 function in replication stress response and checkpoint signaling?

CDC7 plays a crucial role in the replication stress response and checkpoint signaling. Research has shown that upon prolonged fork stalling (e.g., with hydroxyurea treatment), CDC7 inhibition suppresses checkpoint signaling and DNA double-strand break induction . Specifically, loss of DBF4 (but not DRF1) affects CHK1 phosphorylation at Ser345, a downstream marker of ATR activity . This indicates that the CDC7-DBF4 complex is specifically required for full checkpoint activation in response to replication stress. Researchers using CDC7 antibodies to study stress responses should consider these pathway-specific effects and potentially examine both CDC7 and phosphorylated downstream targets.

What are the best methods for validating CDC7 antibody specificity in experimental systems?

When validating CDC7-2 antibody specificity, researchers should implement multiple complementary approaches:

• Genetic validation: Compare antibody reactivity in wild-type cells versus CDC7-knockdown or knockout cells (using siRNA or CRISPR/Cas9) . The absence or significant reduction of signal in knockout/knockdown samples confirms specificity.

• Immunoprecipitation coupled with mass spectrometry: This can identify all proteins pulled down by the antibody to confirm CDC7 as the primary target and reveal potential cross-reactivity.

• Western blotting analysis: CDC7 typically appears at ~64 kDa, while DBF4 appears at ~110 kDa on SDS-PAGE . Validation should include positive controls (cells known to express CDC7) and negative controls.

• Competition assays: Pre-incubation of the antibody with recombinant CDC7 protein should diminish or eliminate the signal if the antibody is specific.

• Cross-validation with multiple antibodies: Using different antibodies targeting distinct CDC7 epitopes should produce consistent results in terms of protein detection and localization.

What are the optimal conditions for immunohistochemistry (IHC) using CDC7 antibodies?

Based on the referenced research protocols, optimal conditions for CDC7 antibody use in IHC include:

• Fixation and processing: Paraffin wax-embedded tissue is suitable for CDC7 IHC .

• Antibody dilution: CDC7 primary antibody has been successfully used at 1:100 dilution in breast and pancreatic cancer studies .

• Controls:

  • Negative control: Incubation without primary antibody

  • Positive control: Colonic epithelium has been used successfully

• Quantification method: Labeling indices (LI) can be determined by counting the percentage of positive cells in representative fields .

• Signal detection: Standard immunoperoxidase-based detection systems are effective for CDC7 visualization in tissue sections.

Note that these conditions may need optimization based on specific tissue types, fixation methods, and the particular CDC7-2 antibody being used.

How can CDC7 antibodies be effectively used in cell cycle analysis experiments?

CDC7 antibodies can be particularly valuable in cell cycle analysis experiments when combined with other markers. Based on experimental approaches in the literature:

• Co-immunofluorescence with cell cycle markers: Combine CDC7 antibody staining with markers such as cyclin A (S/G2 phase), cyclin B1 (G2/M), or Ki-67 (proliferating cells) .

• Dual nucleotide labeling techniques: CDC7 antibody staining can be combined with CldU and IdU incorporation assays to specifically examine CDC7 association with active replication forks . This approach involves:

  • Sequential pulse-labeling cells with CldU and then IdU

  • Fixation and immunodetection using mouse anti-BrdU for IdU and rat anti-BrdU for CldU

  • Counterstaining DNA with DAPI

  • Co-staining with CDC7 antibody to visualize association with replication sites

• FACS analysis: Combine CDC7 antibody staining with DNA content analysis using propidium iodide or DAPI to correlate CDC7 levels with specific cell cycle phases.

• Quantitative image analysis: Confocal microscopy of CDC7-stained cells can be used to quantify nuclear localization and intensity across hundreds of cells (300-500 DAPI-stained nuclei per condition is recommended) .

How can CDC7 antibodies be used to identify potential responders to CDC7 inhibitor therapy?

CDC7 antibodies can serve as companion diagnostic tools to predict response to therapeutic agents targeting CDC7. Research indicates several potential approaches:

• Expression level assessment: High CDC7 expression in tumors correlates with sensitivity to CDC7 inhibition. Immunohistochemistry with standardized CDC7 antibodies can help stratify patients based on expression levels .

• p53 status correlation: Since the sensitivity to CDC7 inhibition is mechanistically linked to p53 mutation status, combining CDC7 immunostaining with p53 status assessment could improve prediction accuracy. Tumors with both high CDC7 expression and mutant p53 may be particularly responsive .

• Checkpoint component analysis: Tumors with inactivating mutations in checkpoint effector proteins (p53, p21, Dkk3, ARF, Hdm2, FoxO3a, p15, p27, and Rb) are predicted to be more susceptible to CDC7 inhibition . Multiplex staining approaches combining CDC7 with antibodies against these checkpoint components could refine patient selection.

• Quantitative thresholds: In pancreatic cancer studies, a median labeling index of 34.3% (IQR 28.6 to 63.4%) was associated with malignancy . Similar quantitative thresholds could potentially be established for other cancer types to guide therapeutic decisions.

What are the challenges in developing CDC7 antibodies for clinical diagnostic applications?

Several challenges exist in translating CDC7 antibodies from research tools to clinical diagnostics:

• Specificity optimization: Ensuring consistent specificity across diverse patient samples with variable fixation and processing methods remains challenging. Clinical-grade antibodies must maintain high specificity across this variability.

• Standardization of scoring: Developing standardized, reproducible scoring systems for CDC7 expression that correlate with therapeutic response. Currently, diverse labeling indices and scoring approaches are used .

• Epitope selection considerations: CDC7-2 antibody epitopes must be carefully selected to distinguish between active CDC7-DBF4 versus CDC7-DRF1 complexes, as research indicates DBF4 is the primary mediator of CDC7's critical functions .

• Tissue-specific validation: Different tumor types may require specific validation of cutoff values and interpretation guidelines for CDC7 immunostaining.

• Integration with molecular testing: Clinical utility would be enhanced by integrating CDC7 antibody testing with assessment of p53 and other checkpoint component mutations to create comprehensive predictive algorithms for CDC7 inhibitor efficacy.

What are the conflicting findings regarding CDC7 targeting in different cancer types?

While CDC7 inhibition shows promise across multiple cancer types, some contradictory findings have emerged:

• Varying sensitivity patterns: Although both pancreatic cancer and breast cancer show sensitivity to CDC7 inhibition, the mechanisms and extent of response vary. In breast cancer, sensitivity is particularly pronounced in Her2-overexpressing and triple-negative subtypes , while pancreatic cancer sensitivity appears more broadly applicable .

• p53 dependency variations: While the p53-dependent checkpoint is critical in determining sensitivity to CDC7 inhibition, some studies suggest additional factors may influence response. The complex interplay between multiple checkpoint effector axes (p53, Rb, etc.) requires further clarification .

• DBF4 versus DRF1 roles: Recent research has revealed that while both DBF4 and DRF1 can support CDC7's essential functions, DBF4 is the primary mediator of CDC7 activity during DNA replication . This contradicts earlier assumptions about potential redundancy between these regulatory subunits.

• Checkpoint response differences: The mechanisms of checkpoint activation following CDC7 inhibition and how these differ between cancer types remain incompletely understood. For instance, the relationship between CDC7 and checkpoint proteins like CHK1 appears complex and context-dependent .

What are emerging applications of CDC7 antibodies in studying chromatin organization and nuclear architecture?

Emerging research suggests expanded roles for CDC7 antibodies in studying higher-order chromatin organization:

• Replication timing domains: CDC7 inhibition or DBF4 deficiency alters replication timing profiles, suggesting roles in organizing replication domain structure . CDC7 antibodies could help map the association of CDC7 with different replication timing domains throughout S phase.

• Relationship with chromatin modifiers: Changes in replication timing observed with CDC7 inhibition have parallels with effects seen when manipulating RIF1-PP1 interactions . This suggests potential interplay between CDC7 and chromatin-modifying factors that could be explored using co-immunoprecipitation with CDC7 antibodies.

• Epigenetic perturbations: Prolonged CDC7 inhibition may lead to epigenetic alterations, a hypothesis requiring further investigation . CDC7 antibodies combined with ChIP-seq approaches could help map how CDC7 localization correlates with specific chromatin modifications.

• Nuclear compartmentalization: How CDC7 contributes to the spatial organization of replication within the nucleus remains poorly understood. Super-resolution microscopy combined with CDC7 antibody staining could reveal patterns of association with nuclear substructures during different cell cycle phases.

How can CDC7 antibodies be optimized for use in chromatin immunoprecipitation (ChIP) experiments?

Optimizing CDC7 antibodies for ChIP requires several specific considerations:

• Crosslinking optimization: Since CDC7 interacts with chromatin indirectly through components of the pre-replication complex, a two-step crosslinking approach may improve results. This typically involves a protein-protein crosslinker (e.g., DSG or EGS) followed by formaldehyde treatment.

• Epitope accessibility: CDC7-2 antibody epitope selection should consider accessibility when CDC7 is bound to chromatin. N-terminal epitopes may be more accessible than C-terminal ones when CDC7 is engaged with the replication machinery.

• Sonication conditions: Optimization of sonication conditions is crucial to generate chromatin fragments of appropriate size (200-500 bp) while preserving CDC7 epitope integrity.

• Controls: Critical controls include:

  • IgG negative control

  • Input DNA

  • Positive control (antibody against known replication fork component)

  • CDC7-depleted cells as specificity control

• Sequential ChIP approaches: To specifically study CDC7-DBF4 versus CDC7-DRF1 complexes, sequential ChIP can be performed using CDC7 antibody followed by DBF4 or DRF1 antibodies to identify sites bound by specific complexes.

What are the most effective research strategies combining CDC7 antibodies with replication stress induction?

Effective experimental strategies combining CDC7 antibodies with replication stress models include:

• Temporal analysis of CDC7 recruitment: Using CDC7 antibodies to track CDC7 recruitment to chromatin at different time points after replication stress induction with agents like hydroxyurea, aphidicolin, or cisplatin .

• Co-localization with stress response proteins: Combining CDC7 antibody staining with antibodies against γH2AX, RPA, or ATR to examine spatial relationships between CDC7 and DNA damage response proteins.

• Isolation of proteins on nascent DNA (iPOND): This technique combined with CDC7 antibody-based detection can reveal how CDC7 association with active and stalled replication forks changes in response to various replication stresses.

• Pulsed field gel electrophoresis (PFGE): Using CDC7 antibodies in combination with PFGE can help determine how CDC7 inhibition or depletion affects genomic stability and the formation of double-strand breaks after replication stress.

• Checkpoint signaling analysis: Combining CDC7 antibody-based immunoprecipitation with phospho-specific antibodies against checkpoint proteins like CHK1 (Ser345) can reveal how CDC7 contributes to checkpoint activation under different stress conditions .

$Note: The tables and detailed research findings mentioned in the requirements would be included here, but they would need to be created based on more specific data than is available in the provided search results.$

What are common technical challenges when using CDC7 antibodies and how can they be addressed?

Researchers frequently encounter several technical issues when working with CDC7 antibodies:

• Background signal in immunostaining:

  • Challenge: Nonspecific nuclear staining can complicate CDC7 detection

  • Solution: Optimize blocking conditions (5% BSA or 10% normal serum from the species of secondary antibody); include additional blocking steps with avidin/biotin if using biotin-based detection systems

• Variable detection in different cell types:

  • Challenge: CDC7 detection may vary across cell lines due to expression level differences

  • Solution: Titrate antibody concentrations for each cell type; consider signal amplification methods for cell types with lower expression

• Cell cycle-dependent epitope masking:

  • Challenge: CDC7 epitopes may be masked when the protein is in complex with other factors

  • Solution: Test multiple fixation protocols; consider mild detergent pre-treatment to improve epitope accessibility

• Distinguishing CDC7-DBF4 from CDC7-DRF1 complexes:

  • Challenge: Standard CDC7 antibodies detect total CDC7 regardless of binding partner

  • Solution: Use co-immunoprecipitation approaches with DBF4 or DRF1-specific antibodies; alternatively, use proximity ligation assays to specifically detect CDC7 in complex with either regulatory subunit

• Western blot detection issues:

  • Challenge: Multiple bands or weak signal in Western blot applications

  • Solution: Optimize lysis conditions to preserve CDC7 integrity; use phosphatase inhibitors to prevent dephosphorylation during sample preparation

How can researchers validate CDC7 antibody results across different experimental systems?

Cross-validation strategies for CDC7 antibody results include:

• Orthogonal detection methods: Confirm antibody-based findings using alternative approaches such as:

  • mRNA expression analysis (RT-qPCR)

  • Tagged CDC7 expression systems

  • Activity-based assays measuring CDC7 kinase function

• Multiple antibody validation: Use at least two different CDC7 antibodies targeting distinct epitopes to confirm results.

• Genetic models: Compare results between:

  • Wild-type cells

  • CDC7 knockdown/knockout models

  • CDC7 inhibitor-treated cells

  • DBF4 or DRF1 deficient cells

• Functional validation: Couple CDC7 detection with functional readouts such as:

  • MCM helicase phosphorylation status

  • Replication fork progression rates

  • Cell cycle distribution profiles

• Cross-species comparison: Validate findings across multiple species when possible, as CDC7 function is evolutionarily conserved.

Implementing these validation approaches ensures that findings with CDC7-2 antibody are robust and representative of true CDC7 biology rather than technical artifacts.

How might CDC7 antibodies contribute to understanding therapy resistance mechanisms?

CDC7 antibodies can play crucial roles in investigating therapy resistance through several research approaches:

• Monitoring CDC7 expression changes: Using CDC7 antibodies to track changes in expression levels before and after treatment with various therapeutic agents. Increased CDC7 expression might serve as an adaptation mechanism to overcome replication stress induced by chemotherapeutics .

• Identifying altered CDC7 localization patterns: Changes in CDC7 subcellular distribution following therapy could represent a resistance mechanism. CDC7 antibodies in immunofluorescence studies can reveal such alterations.

• Detecting CDC7 post-translational modifications: Development of modification-specific CDC7 antibodies (phospho, ubiquitin, etc.) could reveal how CDC7 regulation changes in resistant cells.

• Examining CDC7-complex composition: In resistant cells, CDC7 might preferentially associate with different protein complexes. Immunoprecipitation with CDC7 antibodies followed by mass spectrometry could identify such altered interactions.

• Investigating backup pathways: CDC7 antibodies can help determine whether certain resistance mechanisms involve bypass of CDC7-dependent steps through alternative kinases or pathways.

What is the potential for developing CDC7 complex-specific antibodies for targeted research applications?

Development of complex-specific antibodies represents an important frontier in CDC7 research:

• CDC7-DBF4 complex-specific antibodies: Given the primary role of DBF4 in mediating CDC7's replication functions , antibodies specifically recognizing CDC7 when complexed with DBF4 would be valuable for studying canonical DNA replication.

• CDC7-DRF1 complex-specific antibodies: Although DRF1's role appears more limited , complex-specific antibodies could help elucidate its unique functions.

• Phospho-specific antibodies: Developing antibodies against CDC7 phosphorylated at specific regulatory sites could help distinguish active from inactive forms.

• Conformation-specific antibodies: Antibodies recognizing specific conformational states of CDC7 (such as the active kinase conformation) could provide powerful tools for monitoring CDC7 activation status in situ.

• Epitope-specific considerations: Such complex-specific antibodies would likely target the interface between CDC7 and its regulatory subunits or conformational epitopes that only exist in the assembled complexes.